Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Ascendis Pharma A/S

ASND ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Large Cap Analyst: BUY

Last Close

$248.50

▲ +0.92%

Market Cap $16.32B · Vol 176.21K

Key Metrics

P/E Ratio

19.47

FWD: 18.65

Market Cap

$16.32B

Large Cap

Div Yield

N/A

EPS Growth

+480.09%

YoY

RSI (14)

43.59

Momentum

Beta

0.33

vs Market

52W High

$281.90

11.85% below

52W Low

$186.50

33.24% above

Volume

176.21K

Avg 164.39K

P/B

N/A

Price-to-book

ROE

169.85%

Return on equity

Free Float

96.42%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Ascendis Pharma A/S (ASND) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ASND pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.71%

-6.43%

+1.23%

+14.88%

YTD

+16.54%

+29.40%

+168.65%

+105.37%

Financials & Valuation

TTM · Annual

Total Revenue	$845.79M
Net Income	$-267,824,718.00
Revenue Growth (YoY)	+114.68%
Gross Margin	86.82%
Operating Margin	-18.92%
Net Profit Margin	-31.67%
ROE	169.85%
ROA · ROIC	-17.14% · N/A

P/E Ratio	19.47
Forward P/E (FY1)	18.65
PEG Ratio	N/A
P/S	15.28
P/B	N/A
P/FCF	242.31
EPS Growth	+480.09%
Outstanding Shares	65.67M

Technical Indicators

50-Day SMA	$248.08
200-Day SMA	$228.47
RSI (14)	43.59
Beta	0.33
52-Week High	$281.90
52-Week Low	$186.50

Volume Today	176.21K
Avg Daily Volume (30D)	164.39K
Relative Volume	1.07x
Volatility (10D)	24.84
Volatility (30D)	27.13
Free Float	96.42%

Analyst Consensus

BUY

Current Price $248.50

Mean Target $314.63

52W Low$186.50 52W High$281.90

Current

Target

$186.50 $281.90

Current Analyst target

+26.61% upside potential · 18 analysts

Identifiers

ExchangeNasdaq

FIGIBBG007R7VP72

ISINDK0060615755

CountryDenmark

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Ascendis Pharma A/S is a Denmark?based biopharmaceutical company operating within the life sciences and biotechnology sector. The Company scope of activity includes discovery, development, and commercialization of innovative therapies for rare diseases and serious chronic conditions with significant unmet medical needs where a clinically validated parent drug or pathway is suitable to company technologies. Ascendis Pharma A/S focuses on the endocrinology area and has a pipeline of three independent rare disease product candidates, such as Growth Hormone Deficiency (GHD), Hypoparathyroidism and Achondroplasia. The second therapeutic area is oncology, where the company focuses immunotherapy to targeted therapies.